Selexipag

Selexipag

250px
Names
IUPAC name 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide
Other names ACT-293987, NS-304
Identifiers
CAS Number	475086-01-2 Y
ChEBI	CHEBI:90844 Y
ChEMBL	ChEMBL238804 N
ChemSpider	8089417 Y
IUPHAR/BPS	7552
Jmol 3D model	Interactive image
KEGG	D09994 Y
PubChem	9913767
UNII	P7T269PR6S Y
InChI InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31) Y Key: QXWZQTURMXZVHJ-UHFFFAOYSA-N Y InChI=1/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31) Key: QXWZQTURMXZVHJ-UHFFFAOYAA
SMILES CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
Properties
Chemical formula	C26H32N4O4S
Molar mass	496.6 g·mol−1
Vapor pressure	{{{value}}}
Pharmacology
ATC code	B01AC27
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YN ?)
Infobox references

Selexipag (brand name Uptravi) is a drug developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.

File:MRE 269 skeletal.svg

ACT-333679 or MRE-269, the active metabolite of selexipag

History

The US FDA granted selexipag Orphan Drug status for PAH. It was approved by the US FDA on 22 December 2015. The expected price for the drug in the US is $160,000 to $170,000 per patient before rebates.

See also

• Epoprostenol, another name for prostacyclin
• Analogues of prostacyclin:
  • Beraprost
  • Iloprost
  • Treprostinil